CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00516295
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:37.914193+00:00
Published At: 2014-09-02T00:00:00+00:00
Record Updated At: 2014-09-02
Results Posted At: 2014-09-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ewing Sarcoma of Bone", "Extraosseous Ewing Sarcoma", "Peripheral Primitive Neuroectodermal Tumor", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2014-09-02"
protocolSection.identificationModule.nctId: "NCT00516295"
protocolSection.identificationModule.officialTitle: "A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2014-09-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.